CrossFit Hosts Livestream on Serena Williams' GLP-1 Use, Semaglutide, Tirzepatide

CrossFit put a public spotlight on GLP-1 drugs this week with a panel-style livestream tackling the visibility of semaglutide, tirzepatide and related medicines and the questions that visibility raises for coaching, competition and community norms. The discussion arrived amid a high-profile sponsored post featuring Serena Williams and sought to unpack who benefits from these treatments and what that means for CrossFit gyms.

CrossFit’s official YouTube channel posted a live discussion/replay titled “CrossFit takes on Serena's GLP-1 use” that streamed Feb. 3, 2026. The CrossFit Podcast previously ran a related livestream episode titled “[LIVE] CrossFit, GLP-1s, and the Serena Williams Ad (EP. 034)” on Sept. 11, 2025. The podcast episode lists Denise Thomas as host and names Dr. Tom McCoy, Jocelyn Rylee, and Joe Alexander as guests. CrossFit framed the conversation as an attempt to illuminate the intersection of health, lifestyle interventions and community practice.

CrossFit’s episode copy set the tone: “We’re sitting down to have an honest, nuanced conversation about Ozempic (semaglutide), other GLP-1 drugs, and their role in lifestyle intervention and health.” Organizers said the aim was broad and practical: “We want to understand who benefits, who profits, and what the implications are for individuals, coaches, and the broader CrossFit community.” The description was explicit that the podcast did not present itself as an authoritative medical source: “The goal is not to provide all the answers or be the experts, but to create space for a thoughtful discussion around an important and highly visible issue, especially in light of GLP-1 provider Ro’s recent sponsored post featuring Serena Williams.”

The livestream content is described as exploring GLP-1 receptor agonists (semaglutide, tirzepatide and similar drugs), examining how these medic. That truncated fragment reflects the program copy as posted and signals areas where listeners will want more detail from clinicians and regulatory sources. CrossFit also tied the GLP-1 conversation into core community topics: coaching standards, member experience and affiliate expectations. “In this livestream, hosts James Hobart and Denise Thomas break down the non-negotiables of a great affiliate, as well as stylistic touches that make each gym unique,” the feed reads, alongside lines that urge members, owners and coaches to consider what the “ideal member experience” entails.

For CrossFit coaches and box owners, the practical value of the livestream is a starting place for policy and conversation. The episode prompts affiliates to clarify how they handle medication disclosures, athlete support and coaching guidance tied to weight-loss or metabolic treatments. CrossFit encouraged audience engagement with direct contact: “Let us know what you think –> podcasts@crossfit.com” and “Follow us on YouTube to join future livestreams.” The crew also framed the topic within community standards: “The crew digs into where the standard came from, why it matters, and what happens when we don’t uphold it. They’ll break down coaching, defining fitness, and the ultimate goals of health and performance longevity.”

Next steps for readers are practical: watch the livestream or podcast to hear the full conversation, bring the discussion to your affiliate, and seek medical expertise before drawing conclusions about GLP-1 drugs and training. CrossFit has opened the floor; now coaches, owners and members must translate that dialogue into clear policies and informed practice.